Availability and payer coverage of BRCA1/2 tests and gene panels

Elizabeth Clain,
Julia R Trosman,
Michael P Douglas,
Christine B Weldon
& Kathryn A Phillips

Affiliations
Corresponding author

Nature Biotechnology

33,

900–902

(2015)

doi:10.1038/nbt.3322

Published online: 08 September 2015

To the Editor:

In recent years, genetic testing for heritable cancer syndromes has been shifting from single-gene analysis to multigene panels, typically using next-generation sequencing (NGS) technologies. As a correspondence in your October issue¹ described, despite the increasing use of NGS in clinical practice, regulatory standards remain vague and payers have…